Merck Reports Good News/Bad News In Latest Keytruda Readouts

 
• By Joseph Haas

With successful Phase III data, Merck will look to add biliary tract cancer to Keytruda’s label, but it will discontinue a Phase III study in prostate cancer after an interim analysis showed no survival benefit.

Good & Bad
Merck's Keytruda showed benefit in biliary cancer, but not prostate • Source: Shutterstock

More from Clinical Trials

More from R&D